AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

SELLAS Life Sciences Group, Inc. Director's Dealing 2014

Jan 23, 2014

33651_dirs_2014-01-22_7dd4fea7-576c-4c5c-b486-e60063280659.zip

Director's Dealing

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2014-01-17

Reporting Person: KRIEGSMAN STEVEN A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-01-17	Common Stock	M	200000	$0.85	Acquired	205000	Direct
2014-01-17	Common Stock	S	200000	$7	Disposed	5000	Direct
2014-01-22	Common Stock	M	200000	$1.18	Acquired	205000	Direct
2014-01-22	Common Stock	M	50000	$0.72	Acquired	255000	Direct
2014-01-22	Common Stock	S	250000	$6.13	Disposed	5000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-01-17	Stock Option (right to buy)	$0.85	M	200000	Disposed	2021-09-27	Common Stock (200000)	Direct
2014-01-22	Stock Option (right to buy)	$1.18	M	200000	Disposed	2021-03-24	Common Stock (200000)	Direct
2014-01-22	Stock Option (right to buy)	$0.72	M	50000	Disposed	2022-01-12	Common Stock (50000)	Direct